연구동향 분석

Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease

Yeoun Joo Lee Jae Hong Park 2022년

논문상세정보
인용/피인용
' Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Child
  • Leukocyte L1 Antigen Complex
  • biomarker
  • crohn disease
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,410 0

0.0%

' Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease' 의 참고문헌

  • Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease
    Tibble JA [2002]
  • Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : determining therapeutic goals for treat-to-target
  • Predictors of longterm clinical and endoscopic remission in children with Crohn disease treated with infliximab
  • Predicting endoscopic Crohn’s disease activity before and after induction therapy in children : a comprehensive assessment of PCDAI, CRP, and fecal calprotectin
    Zubin G [2015]
  • Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery
    Wright EK [2015]
  • Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients : a plea for deep remission
    Mooiweer E [2015]
  • Fecal markers of inflammation and disease activity in pediatric Crohn disease : results from the ImageKids study
    Leach ST [2020]
  • Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn’s disease
    Beltrán B [2019]
  • Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
    Kostas A [2017]
  • Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease
    Copova I [2018]
  • Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    D’Haens G [2012]
  • Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon : a prospective study
    Kallel L [2010]
  • Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease(SES-CD)than CRP, blood leukocytes, and the CDAI
  • Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
    Gisbert JP [2009]
  • Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease : prediction of clinical response and mucosal healing at one year
    Guidi L [2014]
  • Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment
    Sipponen T [2010]
  • Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease
    Pavlidis P [2016]
  • Development and validation of a new, simplified endoscopic activity score for Crohn's disease : the SES-CD
    Daperno M [2004]
  • Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings
    Sipponen T [2008]
  • Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
    Foster AJ [2019]
  • Association of faecal calprotectin level and combined endoscopic and radiological healing in patients with Crohn’s disease receiving anti-tumour necrosis factor therapy
    Noh SM [2020]
  • Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
    Lee Yoo Min [2022]
  • Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease
    Jusué V [2018]
  • Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy : a prospective longitudinal cohort study